STAR Stock Overview
Develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Strides Pharma Science Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹615.30 |
| 52 Week High | ₹1,675.00 |
| 52 Week Low | ₹513.05 |
| Beta | 0.67 |
| 1 Month Change | 4.72% |
| 3 Month Change | -4.92% |
| 1 Year Change | -26.74% |
| 3 Year Change | 69.71% |
| 5 Year Change | 78.45% |
| Change since IPO | -31.30% |
Recent News & Updates
Recent updates
US Product Launches And ESG Leadership Will Strengthen Future Market Position
Feb 10 Streamlined focus on high-margin operations and U.S. market expansion indicate a strong growth trajectory and improved future earnings.Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors
Nov 01
Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge
Oct 21After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar
Aug 14Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)
Apr 04Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story
Dec 23We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 02Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50
Jul 28Shareholder Returns
| STAR | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.3% | -0.7% | -0.5% |
| 1Y | -26.7% | 10.5% | -2.4% |
Return vs Industry: STAR underperformed the Indian Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: STAR underperformed the Indian Market which returned -2.4% over the past year.
Price Volatility
| STAR volatility | |
|---|---|
| STAR Average Weekly Movement | 8.9% |
| Pharmaceuticals Industry Average Movement | 7.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in IN Market | 9.9% |
| 10% least volatile stocks in IN Market | 5.0% |
Stable Share Price: STAR's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: STAR's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 3,065 | Badree Komandur | www.strides.com |
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams.
Strides Pharma Science Limited Fundamentals Summary
| STAR fundamental statistics | |
|---|---|
| Market cap | ₹56.71b |
| Earnings (TTM) | ₹3.42b |
| Revenue (TTM) | ₹45.79b |
16.6x
P/E Ratio1.2x
P/S RatioIs STAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STAR income statement (TTM) | |
|---|---|
| Revenue | ₹45.79b |
| Cost of Revenue | ₹19.74b |
| Gross Profit | ₹26.05b |
| Other Expenses | ₹22.63b |
| Earnings | ₹3.42b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 37.15 |
| Gross Margin | 56.89% |
| Net Profit Margin | 7.48% |
| Debt/Equity Ratio | 104.2% |
How did STAR perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield-18%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/12 12:40 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Strides Pharma Science Limited is covered by 20 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aditya Khemka | Ambit Capital |
| Harith Ahamed | Avendus Spark |
| Prakash Agarwal | Axis Capital Limited |